These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 6404709)

  • 1. Glucose tolerance and chelation therapy in patients with thalassaemia major.
    Capra L; Atti G; De Sanctis V; Candini G
    Haematologica; 1983; 68(1):63-8. PubMed ID: 6404709
    [No Abstract]   [Full Text] [Related]  

  • 2. Epidemiology and chelation therapy effects on glucose homeostasis in thalassaemic patients.
    Gamberini MR; Fortini M; Gilli G; Testa MR; De Sanctis V
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():867-9. PubMed ID: 10091159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased risk of diabetes mellitus in beta- thalassemia major due to iron overload.
    Zuppinger K; Molinari B; Hirt A; Imbach P; Gugler E; Tönz O; Zurbrügg RP
    Helv Paediatr Acta; 1979; 34(3):197-207. PubMed ID: 500381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Continuous subcutaneous deferoxamine infusions in thalassemia major. Improvement in glucose tolerance].
    Krüger N; Stubbe P; Tillmann W; Schröter W
    Dtsch Med Wochenschr; 1986 May; 111(18):698-701. PubMed ID: 3486106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early iron chelation therapy in thalassemia major.
    Russo G; Romeo MA; Musumeci S; Schilirò G; Di Gregorio F
    Haematologica; 1983; 68(1):69-73. PubMed ID: 6404710
    [No Abstract]   [Full Text] [Related]  

  • 6. [Thalassemia major: chelating therapy with deferoxamine].
    Abreu de Miani MS; Sanchis de Herrlein MS; Peñalver JA
    Medicina (B Aires); 1985; 45(3):231-4. PubMed ID: 3841934
    [No Abstract]   [Full Text] [Related]  

  • 7. Iron excretion in thalassemia after the administration of chelating agents.
    Markum AH; Iskandar W; Keng KL; Odang O
    Paediatr Indones; 1969; 9(3):89-98. PubMed ID: 4981722
    [No Abstract]   [Full Text] [Related]  

  • 8. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ; Grady RW
    Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron absorption in non-transfused iron loading anaemias: prediction of risk for iron loading, and response to iron chelation treatment, in beta thalassaemia intermedia and congenital sideroblastic anaemias.
    Pippard MJ; Weatherall DJ
    Haematologia (Budap); 1984; 17(1):17-24. PubMed ID: 6724353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The development of diabetes mellitus and chronic liver disease in long term chelated beta thalassaemic patients.
    De Sanctis V; D'Ascola G; Wonke B
    Postgrad Med J; 1986 Sep; 62(731):831-6. PubMed ID: 3543913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucose tolerance and beta-cell secretion in patients with thalassaemia major.
    Mangiagli A; Italia S; Campisi S
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():985-6. PubMed ID: 10091179
    [No Abstract]   [Full Text] [Related]  

  • 13. [Role and therapeutic use of deferoxamine in iron overload due to thalassemia (author's transl)].
    Lévy G; Bachelot C; Joannard A; Bost M
    Arch Fr Pediatr; 1980 May; 37(5):299-303. PubMed ID: 7469704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desferrioxamine: its use in iron chelation in thalassemia.
    Sharma BK; Choudhury P; Dubey AP
    Indian Pediatr; 1990 Mar; 27(3):314-9. PubMed ID: 2190932
    [No Abstract]   [Full Text] [Related]  

  • 15. Liver iron overload and liver fibrosis in thalassemia.
    Angelucci E; Baronciani D; Lucarelli G; Giardini C; Galimberti M; Polchi P; Martinelli F; Baldassarri M; Muretto P
    Bone Marrow Transplant; 1993; 12 Suppl 1():29-31. PubMed ID: 8374556
    [No Abstract]   [Full Text] [Related]  

  • 16. Thalassemia.
    Brown EB
    Prog Clin Biol Res; 1983; 127():33-42. PubMed ID: 6889403
    [No Abstract]   [Full Text] [Related]  

  • 17. Endocrine complications in thalassaemia major.
    De Sanctis V; Vullo C; Katz M; Wonke B; Hoffbrand VA; Di Palma A; Bagni B
    Prog Clin Biol Res; 1989; 309():77-83. PubMed ID: 2780752
    [No Abstract]   [Full Text] [Related]  

  • 18. [Evaluation of the efficacy of chelation therapy with deferoxamine in patients with thalassemia major].
    Rodríguez Galindo C; Ortega Aramburu JJ; Alonso JL; Albisu M; Casaldáliga J; Díaz de Heredia C; Olivé T; Bastida P
    Med Clin (Barc); 1994 May; 102(19):721-4. PubMed ID: 8041200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zinc deficiency aggravates abnormal glucose metabolism in thalassemia major patients.
    Dehshal MH; Hooghooghi AH; Kebryaeezadeh A; Kheirabadi M; Kazemi S; Nasseh A; Shariftabrizi A; Pasalar P
    Med Sci Monit; 2007 May; 13(5):CR235-9. PubMed ID: 17476196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Thalassemic cardiopathy: serial echocardiographic evaluation].
    Bosi S; Spinolo L; Cavallini B; Guadagni C; Lama A; Santarelli R; Baccini C
    G Clin Med; 1982 Apr; 63(4):248-54. PubMed ID: 7128980
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.